Key result
Higher baseline sST2 in chronic HF linked to ~3% greater long-term mortality risk.
Why the study?
Soluble suppression of tumorigenicity-2 is considered a prognostic factor in cardiovascular disease, but its prognostic value in chronic heart failure remained to be summarized.
Does higher circulating sST2 concentration predict mortality and heart failure readmission in patients with chronic heart failure?
Meta-Analysis (n=5,121)
Does higher circulating sST2 concentration predict mortality and heart failure readmission in patients with chronic heart failure?
Effect estimate: HR 1.03 (95% CI 1.02-1.04)
Higher baseline sST2 concentration is a significant prognostic biomarker for increased risk of long-term mortality and heart failure readmission in patients with chronic heart failure.
Strengthens sST2 for mortality risk stratification in chronic HF; confirms association in meta-analysis of observational data.
INTRODUCTION: Soluble suppression of tumorigenicity-2 (sST2) has been considered as a prognostic factor of cardiovascular disease. However, the prognostic value of sST2 concentration in chronic heart failure remains to be summarized. METHODS: We searched PubMed, Embase, and Web of Science for eligible studies up to January 1, 2020. Data extracted from articles and provided by authors were used in agreement with the PRISMA statement. The endpoints were all-cause mortality (ACM), cardiovascular mortality (CVM)/heart failure-related hospitalization (HFH), and all-cause mortality (ACM)/heart failure-related readmission (HFR). RESULTS: A total of 11 studies with 5,121 participants were included in this analysis. Higher concentration of sST2 predicted the incidence of long-term ACM (hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 1.02-1.04), long-term ACM/HFR (HR: 1.42, CI: 1.27-1.59), and long-term CVM/HFH (HR: 2.25, CI: 1.82-2.79), regardless of short-term ACM/HFR (HR: 2.31, CI: 0.71-7.49). CONCLUSION: Higher sST2 concentration at baseline is associated with increasing risk of long-term ACM, ACM/HFR, and CVM/HFH and can be a tool for the prognosis of chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2021) conducted a meta-analysis in chronic heart failure (n=5,121). Soluble suppression of tumorigenicity-2 (sST2) concentration was evaluated on long-term all-cause mortality (ACM) (HR 1.03, 95% CI 1.02-1.04). Higher baseline sST2 concentration in chronic heart failure was associated with an increased risk of long-term all-cause mortality (HR 1.03; 95% CI 1.02-1.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: